Impact of THC on E-Cigarette Use Behavior
Effect of Cannabinoids on Tobacco Product Demand and Pharmacodynamics: Electronic Cigarette Use
This study is testing how different doses of THC affect daily e-cigarette users' cravings and use behavior.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | Johns Hopkins University Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT06609109 on ClinicalTrials.gov |
What this trial studies
This study investigates how tetrahydrocannabinol (THC) affects the use of electronic cigarettes among daily users. It employs a double-blind, placebo-controlled, within-subjects crossover design to assess the motivational, subjective, and physiological responses to varying doses of THC. Participants will be administered either smoked or vaporized THC while their e-cigarette use, cravings, heart rate, blood pressure, and cognitive performance are monitored. The goal is to understand the relationship between THC and e-cigarette behavior in a controlled laboratory setting.
Who should consider this trial
Good fit: Ideal candidates are healthy adults aged 21 or older who are daily e-cigarette users and consume cannabis at least once a week.
Not a fit: Patients intending to quit or reduce their cannabis or tobacco use within the next 30 days may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into how THC influences e-cigarette use, potentially informing harm reduction strategies for tobacco and cannabis users.
How similar studies have performed: While studies on cannabis and tobacco use exist, this specific approach examining the acute effects of THC on e-cigarette behavior is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: 1. Healthy non-treatment seeking adults aged 21 or older 2. Report daily use of e-cigarettes 3. Biological confirmation of e-cigarette use: have a positive urine cotinine test at screening 4. Report current use of cannabis (at least 1 occasion per week) 5. Have experience with the inhalation route of administration for cannabis 6. Biological confirmation of cannabis use: have a positive urinary THC drug test at screening. 7. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study. Exclusion criteria: 1. Report current intention to reduce or quit cannabis or tobacco use within the next 30 days 2. Meet Diagnostic and Statistical Manual (DSM-5) criteria for a substance use disorder other than alcohol, cannabis, or nicotine 3. Test positive for illicit drugs other than cannabis and tobacco 4. Positive breath alcohol test at study admission 5. Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity 6. Have a lifetime history of suicidal behavior (i.e. past suicide attempt), or current suicidal behavior or ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) 7. Are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding 8. Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina) 9. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.
Where this trial is running
Baltimore, Maryland
- Johns Hopkins University Behavioral Pharmacology Research Unit — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Dustin Lee, PhD — Johns Hopkins School of Medicine
- Study coordinator: Lauren Brogdon, MHS
- Email: lmorri20@jhmi.edu
- Phone: 410-550-6953
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.